Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,770.00down ₹7.70 (0.43%)BSE ₹1,768.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,777.70.
2 Nov: open ₹1,770.00, high ₹1,776.20, low ₹1,722.00
52-week range of traded prices to 2 Nov 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,24,682 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.73
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,57,79149.8% delivered
Sun Pharmaceutical Industries share news and announcements
1,454 announcements, routine notices left out, newest first. Page 22 of 30.
May 2014
16 May · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma moves SC against stay on Ranbaxy merger". The Company has clarified that "The facts mentioned under the referred news article are largely true. We further state that there is no material impact of the matter on the process of completion of merger of Ranbaxy Laboratories Ltd with our Company".13 May · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun Pharma recalls over 4 lakh bottles of two drugs in US". The Company has clarified that "The details mentioned in the said article are correct. However, since the recall entails only a few batches of the said drugs from the US market, the overall impact on our sales is negligible. Hence in our view the above information did not/ does not constitute price sensitive information".12 May · Disclosure of Voting Pattern - Clause 35A
5 May · Legal
Exchange had sought clarification from Sun Pharmaceuticals Industries Limited with respect to a news item captioned "Sun-Ranbaxy deal hits hurdle". The Company has clarified that "We were not served the notice of the hearing for the AP High Court case referred to and the matter was decided ex parte. Please further note that our subsidiary llp, Silver Street Developers LLP had bought the Ranbaxy shares when we had no access to non-public information of Ranbaxy. We hereby confirm that we had not bought any shares in the period from 1st April to 7th April. Specifically, we had no role to play in the trading that happened in the week prior to the announcement wherein the share price of Ranbaxy went up. Silverstreet had previously bought these shares as a matter of investment. Pl. note at Sun Pharma, we always hold ourselves to the highest standards of corporate governance and business ethics. We believe that, as advised by our advisers , the article/judgement would not have material impact on the merger process of Ranbaxy with our Company".
Apr 2014
21 Apr · Court Convened Meeting Updates
Mar 2014
Feb 2014
13 Feb · Management
Board Of Directors of the Company at its meeting held on February 13, 2014 has appointed Ms. Rekha Sethi as an Additional Independent Director on the Board of Directors of the Company.
Jan 2014
27 Jan · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2013.
Dec 2013
Nov 2013
14 Nov · Business
Board of Directors of the Company has, passed Resolution on November 13, 2013, approving, subject to the approval of the respective governmental and regulatory authorities at UAE, if required and approval of SEBI, Stock Exchanges, the High Court of Gujarat at Ahmedabad, Shareholders and Creditors of the Company, and other required governmental and/or regulatory authorities, as may be required, the Scheme of Arrangement under Sections 391 to 394 of the Companies Act, 1956 for spin off of the Specified Therapeutic and Investment Business Undertakings of Sun Pharma Global FZE, a wholly owned subsidiary of Sun Pharma Global Inc., which is a wholly owned subsidiary of the Company, into the Company, Sun Pharmaceutical Industries Ltd without any consideration with effect from May 01, 2013 as per the Scheme of Arrangement.
Oct 2013
28 Oct · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the second quarter / half year ended September 30, 2013.
Sep 2013
Aug 2013
13 Aug · Corporate action
Company has fixed Book Closure from September 23, 2013 to September 30, 2013 (both days inclusive) for the purpose of the Annual General Meeting of the Company and for the payment of dividend.13 Aug · Dividend
Payment of dividend if approved and declared at the ensuing Annual General Meeting by the shareholders would be made on or after October 04, 2013.
Jul 2013
24 Jul · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the first quarter ended June 30, 201319 Jul · Corporate action
Company has fixed Record Date as July 30, 2013 in order to determine the names of Members who are entitled to receive Bonus Equity shares in the ratio of 1:1 (i.e. one equity share of Re.1 each for every equity share of Re.1 each held by the shareholders).16 Jul · Disclosure of Voting Pattern - Clause 35A
Jun 2013
May 2013
28 May · News Verification
News Verification : The media had reports that Sun Pharmaceuticals Industries Limited may acquire Germany-based company Stada. . The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharmaceuticals Industries Limited has vide its letter inter-alia stated, "We have absolutely no comment on market speculation. Please further note since we have large cash and cash equivalents, we are constantly linked to rumours of international acquisition. We further confirm that if and when we make any announcement regarding any material activity for our business, we will ensure that we follow the mandated procedure of informing the stock exchange first."28 May · Corporate action
Board of Directors of the Company at its meeting held on May 28, 2013 has recommended the issue of Bonus Equity shares of Re.1 each subject to the receipt of approval of the equity shareholders of the Company, to the equity shareholders of the Company in the ratio of 1(one) equity share for every 1 (one) no. of equity shares held by equity shareholders in the Company, as on the record date to be fixed by the Board after receiving approval from the shareholders for issue of such bonus shares.28 May · Dividend
Board of Directors of the Company at its meeting held on May 28, 2013 has recommended payment of dividend of Rs. 5 (Rupees Five) per equity share of Re. 1/- each of the Company (pre bonus as recommended as below) for the year ended March 31, 2013 subject to the approval of the members at the ensuing Annual General Meeting of the Company.